Commitments and Contingencies - Narrative (Details) $ in Thousands |
Jun. 30, 2024
CAD ($)
|
Jun. 30, 2024
USD ($)
|
Dec. 31, 2023
USD ($)
|
---|---|---|---|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial liabilities measured at fair value | $ 1,878,000 | ||
Liability for Contingent Consideration | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial liabilities measured at fair value | $ 0 | $ 1,878,000 | |
Kairos Acquisition | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Contingent liability | $ 8,500 | ||
Kairos Acquisition | First Phase 2 Trial | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Contingent liability | 2,500 | ||
Kairos Acquisition | First Phase 3 Trial | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Contingent liability | $ 6,000 |